RecruitingNCT06316466

Lipoprotein a is an Independent Risk Factor for Overall Survival in Patients With Pancreatic Cancer: a Propensity Score Matching Analysis

Sponsor

jingxue

Enrollment

360 participants

Start Date

Jun 1, 2023

Study Type

OBSERVATIONAL

Conditions

Pancreatic Carcinoma; Lipoprotein a; Overall Survival; Prognosis

Summary

Background: This study aims to assess the prognostic significance of serum lipoprotein (a) \[Lp (a)\] levels on overall survival (OS) and progression free survival (PFS) in individuals diagnosed with pancreatic cancer through the utilization of propensity score matching (PSM). Methods: A retrospective analysis was conducted on the clinicopathological data of 364 patients diagnosed with pancreatic cancer at the Affiliated Hospital of Qingdao University from January 2019 to December 2022. The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups. We applied PSM analysis to minimize selection bias. The study compared OS and PFS between two groups by Kaplan-Meier method and analyzed differences using the log-rank test. Additionally, univariate and multivariate Cox-regression analyses were performed to identify prognostic factors among patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an observational study analyzing whether high levels of lipoprotein(a) — a type of fat particle in the blood associated with heart disease risk — also independently predicts worse survival outcomes in patients with pancreatic cancer. Researchers review existing patient records and use statistical matching techniques to isolate this factor. **You may be eligible if...** - You are an adult (18 years or older) - You have a confirmed diagnosis of pancreatic cancer from surgery or a biopsy - A complete lipid panel (blood fat test) is available from within one week before your diagnosis **You may NOT be eligible if...** - You have another active cancer at the same time - You have already received treatment for pancreatic cancer (surgery, chemotherapy, or radiation) before the lipid test was taken - Your medical records are incomplete Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERLp(a)

The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.

Locations(1)

Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06316466